Profile of adalimumab and its potential in the treatment of uveitis

References

• DunnJPUveitisPrim Care201542330532326319340
   PubMed Web of Science ®Google Scholar
• JabsDANussenblattRBRosenbaumJTStandardization of Uveitis Nomenclature Working GroupStandardization of uveitis nomenclature for reporting clinical data. Results of the First International WorkshopAm J Ophthalmol2005140350951616196117
   PubMed Web of Science ®Google Scholar
• PasadhikaSRosenbaumJTUpdate on the use of systemic biologic agents in the treatment of noninfectious uveitisBiologics20148678124600203
   PubMedGoogle Scholar
• TraceyDKlareskogLSassoEHSalfeldJGTakPPTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther2008117224427918155297
   PubMed Web of Science ®Google Scholar
• NeriPZucchiMAllegriPLettieriMMariottiCGiovanniniAAdalimumab (Humira): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmologyInt Ophthalmol201131216517321287227
   PubMedGoogle Scholar
• FeldmannMDevelopment of anti-TNF therapy for rheumatoid arthritisNat Rev Immunol20022536437112033742
   PubMed Web of Science ®Google Scholar
• DickADImmune mechanisms of uveitis: insights into disease pathogenesis and treatmentInt Ophthalmol Clin200040211810791254
   PubMedGoogle Scholar
• CurnowSJFalcianiFDurraniOMMultiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitisInvest Ophthalmol Vis Sci200546114251425916249505
   PubMed Web of Science ®Google Scholar
• MoJSMatsukawaAOhkawaraSYoshinagaMInvolvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitisExp Eye Res19986655475579628802
   PubMed Web of Science ®Google Scholar
• Humira® (adalimumab) [prescribing information]IllinoisAbbVie, Inc2016
   Google Scholar
• SimoniniGTaddioACattaliniMPrevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximabArthritis Care Res (Hoboken)201163461261821452272
   PubMed Web of Science ®Google Scholar
• Vazquez-CobianLBFlynnTLehmanTJAdalimumab therapy for childhood uveitisJ Pediatr2006149457257517011337
   PubMed Web of Science ®Google Scholar
• HamamRNBarikianAWAntoniosRSIntravitreal adalimumab in active noninfectious uveitis: a pilot studyOcul Immunol Inflamm201624331932625549063
   PubMed Web of Science ®Google Scholar
• NestorovIClinical pharmacokinetics of tumor necrosis factor antagonistsJ Rheumatol Suppl200574131815742459
   PubMedGoogle Scholar
• NestorovIClinical pharmacokinetics of TNF antagonists: how do they differ?Semin Arthritis Rheum2005345 Suppl 1121815852249
   PubMed Web of Science ®Google Scholar
• GrannemanRGZhangYNoertersheuserPAVelagapudiRBAwniWMLockeCSPharmacokinetic/Pharmacodynamic (PK/PD) Relationships of Adalimumab (HUMIRA™) in Rheumatoid Arthritis (RA) Patients During Phase II/III Clinical Trials (Poster 2562003)Poster presented at: ACR Annual Scientific MeetingOctober 24–28, 2003Orlando, FL
   Google Scholar
• RabinovichCEUse of tumor necrosis factor inhibitors in uveitisCurr Opin Rheumatol200719548248617762615
   PubMed Web of Science ®Google Scholar
• HeinzCMingelsAGoebelCFuchslugerTHeiligenhausAChronic uveitis in children with and without juvenile idiopathic arthritis: differences in patient characteristics and clinical courseJ Rheumatol20083571403140718484686
   PubMed Web of Science ®Google Scholar
• RamananAVDickADBentonDA randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)Trials2014151424405833
   PubMed Web of Science ®Google Scholar
• RamananAVDickADMcKayAA randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis [abstract]Arthritis Rheumatol201567Suppl 10
   Google Scholar
• SimoniniGDruceKCimazRMacfarlaneGJJonesGTCurrent evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugsArthritis Care Res (Hoboken)20146671073108424740981
   PubMed Web of Science ®Google Scholar
• ZanninMEBiroloCGerloniVMSafety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow up data from the Italian RegistryJ Rheumatol2013401747923118110
   PubMed Web of Science ®Google Scholar
• Levy-ClarkeGJabsDAReadRWRosenbaumJTVitaleAVan GelderRNExpert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disordersOphthalmology20141213785796.e324359625
   PubMed Web of Science ®Google Scholar
• Tugal-TutkunIOnalSAltan-YayciogluRHuseyin AltunbasHUrganciogluMUveitis in Behcet disease: an analysis of 880 patientsAm J Ophthalmol2004138337338015364218
   PubMed Web of Science ®Google Scholar
• AridaAFragiadakiKGiavriESfikakisPPAnti-TNF agents for Behcet’s disease: analysis of published data on 369 patientsSemin Arthritis Rheum2011411617021168186
   PubMed Web of Science ®Google Scholar
• ValletHRiviereSSannaAEfficacy of anti-TNF alpha in severe and/or refractory Behcet’s disease: multicenter study of 124 patientsJ Autoimmun201562677426162757
   PubMed Web of Science ®Google Scholar
• Riancho-ZarrabeitiaLCalvo-RioVBlancoRAnti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patientsSemin Arthritis Rheum201545336136826092330
   PubMed Web of Science ®Google Scholar
• BodaghiBTouitouVFardeauCChapelonCLeHoangPOcular sarcoidosisPresse Med2012416 Pt 2e349e35422595776
   PubMedGoogle Scholar
• LeeSYLeeHGKimDSKimJGChungHYoonYHOcular sarcoidosis in a Korean populationJ Korean Med Sci200924341341919543502
   PubMed Web of Science ®Google Scholar
• ErckensRJMostardRLWijnenPASchoutenJSDrentMAdalimumab successful in sarcoidosis patients with refractory chronic noninfectious uveitisGraefes Arch Clin Exp Ophthalmol2012250571372022119879
   PubMed Web of Science ®Google Scholar
• JamillouxYKodjikianLBroussolleCSevePSarcoidosis and uveitisAutoimmun Rev201413884084924704868
   PubMed Web of Science ®Google Scholar
• ZeboulonNDougadosMGossecLPrevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature reviewAnn Rheum Dis200867795595917962239
   PubMed Web of Science ®Google Scholar
• RosenbaumJTUveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel diseaseClin Rheumatol2015346999100225953065
   PubMed Web of Science ®Google Scholar
• RudwaleitMRodevandEHolckPAdalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label studyAnn Rheum Dis200968569670118662932
   PubMed Web of Science ®Google Scholar
• Diaz-LlopisMSalomDGarcia-de-VicunaCTreatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patientsOphthalmology201211981575158122525047
   PubMed Web of Science ®Google Scholar
• SuhlerEBLowderCYGoldsteinDAAdalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trialBr J Ophthalmol201397448148623376607
   PubMed Web of Science ®Google Scholar
• DurraniKKempenJHYingGSAdalimumab for ocular inflammationOcul Immunol Inflamm20161827003323
   PubMedGoogle Scholar
• DiakPSiegelJLa GrenadeLChoiLLemerySMcMahonATumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug AdministrationArthritis Rheum20106282517252420506368
   PubMed Web of Science ®Google Scholar
• ParkHJRanganathanPTNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?Discov Med2012137022923422463799
   PubMed Web of Science ®Google Scholar
• MarietteXMatucci-CerinicMPavelkaKMalignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysisAnn Rheum Dis201170111895190421885875
   PubMed Web of Science ®Google Scholar
• SchmelingHMindenKFoeldvariIGanserGHospachTHorneffGEfficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA RegistryArthritis Rheumatol20146692580258924942886
   PubMed Web of Science ®Google Scholar
• BiesterSDeuterCMichelsHAdalimumab in the therapy of uveitis in childhoodBr J Ophthalmol200791331932417035274
   PubMed Web of Science ®Google Scholar
• Bravo-LjubeticLPeralta-CalvoJNovalSPastora-SalvadorNAbelairas-GomezJMerinoRAdalimumab therapy for refractory childhood uveitisJ AAPOS201317545645924160962
   PubMed Web of Science ®Google Scholar
• TynjalaPKotaniemiKLindahlPAdalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitisRheumatology (Oxford)200847333934418238789
   PubMed Web of Science ®Google Scholar
• KotaniemiKSailaHKautiainenHLong-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritisClin Ophthalmol201151425142922034564
   PubMedGoogle Scholar
• SenESSharmaSHinchcliffeADickADRamananAVUse of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease – a case cohort interventional studyRheumatology (Oxford)201251122199220322923752
   PubMed Web of Science ®Google Scholar
• LermanMARabinovichCEThe future is now: biologics for non-infectious pediatric anterior uveitisPaediatr Drugs201517428330125893479
   PubMed Web of Science ®Google Scholar